双联抗血小板治疗急性冠脉综合征临床疗效观察

目的:探讨双联抗血小板治疗急性冠脉综合征(ACS)的临床疗效和安全性。方法:60例ACS患者随机分为治疗组和对照组。对照组给予阿司匹林单抗血小板治疗,治疗组采用阿司匹林+氯吡格雷双联抗血小板治疗,治疗3个月后评价临床疗效。结果:治疗组临床疗效总有效率为93.3%,显著高于对照组(76.7%),相比较有显著性差异(P<0.05);治疗后,两组LVEF、CO、E/A显著上升,与治疗前比较均有显著性差异(P<0.05);且治疗组与对照组比较有显著性差异(P<0.05)。结论:阿司匹林和氯吡格雷双联抗血小板药物治疗ACS,可以强化对血小板聚集的抑制,并增强抗栓效果,值得临床应用。

Clinical study of dual anti-platelet for patients with acutecoronary syndrome

Objective: To investigate the clinical efficacy and safety of dual anti-platelet for treating the patients with acute coronarysyndrome (ACS).Methods: A total of 60 patients with ACS were randomly divided into the treatment group and control group. The controlgroup''s patients were given the mono anti-platelet therapy of aspirin, and the treatment group''s patients were given the dual anti-platelettreatment of aspirin combined with clopidogrel. The clinical efficacy was observed after treatment for 3 months. Results: The total effectiverate of treatment group was 93.3%, the control group was 76.7%, compared the difference was significant (P <0.05); After therapythe LVEF, CO and E / A of the two groups increased significantly, compared with the prior-treatment the difference was significant (P<0.05), and the difference was significant between the treatment group and control group (P <0.05). Conclusion: The dual anti-platelet ofaspirin combined with clopidogrel for treating the patients with ACS can enhance the inhibition of platelet aggregation and enhance theantithrombotic effect. It is worthy of clinical application.